In an exciting new development in cancer therapy, researchers at the National University of Singapore (NUS) have unveiled a groundbreaking gene delivery technology designed to enhance the effectiveness of cancer-fighting immune cells. This innovative platform, known as Nanostraw Electro-actuated Transfection (NExT), marks a significant advancement in delivering genetic material to human immune cells, potentially paving the way for more accessible and affordable cancer treatments.
A Breakthrough in Gene Delivery
The NExT system offers a scalable and non-viral solution for inserting a wide array of biomolecules—such as proteins, mRNA, and gene-editing tools—into immune cells. This process utilizes tiny hollow nanostructures, referred to as “nanostraws,” and mild electrical pulses to create temporary pores in cell membranes, allowing the genetic material to enter with remarkable efficiency and minimal disruption. This approach addresses several limitations of current methods, notably those concerning safety and cell damage.
Led by Assistant Professor Andy Tay, the NUS team demonstrated that NExT could transfect over 14 million cells in a single run, including challenging cell types, such as gamma-delta T cells and natural killer cells. With a transfection efficiency of up to 94% for proteins and over 80% for mRNA, the NExT platform maintains the immune cells’ essential functions, crucial for effective cancer therapy.
Potential for Affordable, Widespread Cancer Therapy
Cancer, a global health challenge, claims approximately 10 million lives annually. Among newer treatment strategies, CAR-T cell therapy has shown promise, particularly for blood cancers. However, its high cost—around S$670,000 per infusion in Singapore—and the logistical complexities involved have limited broader patient access.
The NExT platform could transform this scenario by reducing production costs and improving the manufacturing consistency of engineered cell products. This innovation aligns well with the Singapore Ministry of Health’s recent move, which, as of August 2024, provides subsidies for clinically and cost-effective cell, tissue, and gene therapy products.
Leaving Industry Giants Behind
Current gene delivery methods like viral vectors and bulk electroporation present challenges in terms of safety and efficiency. The NExT approach sidesteps these issues by simplifying gene delivery, making it an attractive alternative for widespread clinical applications. The technology’s ability to handle diverse immune cell types extends its potential beyond traditional CAR-T therapies, potentially enhancing a range of immunotherapy strategies.
Looking forward, the NUS team plans to validate this platform in preclinical studies and seek industry collaborations to integrate NExT into existing cell therapy workflows. This move could streamline the development and distribution of advanced cancer treatments, ultimately benefiting patients globally.
Key Takeaways
-
Innovative Technology: The NExT platform from NUS is a non-viral, scalable gene delivery system that uses nanostraws and mild electrical pulses to effectively and safely transfect immune cells.
-
High Efficiency, Low Cost: This system can deliver essential biomolecules with up to 94% efficiency while reducing costs, potentially increasing accessibility to powerful cancer therapies like CAR-T.
-
Wide Applicability: By efficiently transfecting a broad range of immune cells, NExT supports diverse therapy options, including allogeneic treatments, that could be available off-the-shelf.
-
Future Prospects: As NExT progresses towards clinical trials, it offers the promise of revolutionizing cancer treatment by making cutting-edge therapies more affordable and accessible, marking a significant leap forward in the fight against cancer.